Town & Country Bank & Trust CO dba First Bankers Trust CO Sells 75 Shares of Amgen Inc. (NASDAQ:AMGN)

Town & Country Bank & Trust CO dba First Bankers Trust CO reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 4.6% during the first quarter, Holdings Channel.com reports. The institutional investor owned 1,545 shares of the medical research company’s stock after selling 75 shares during the period. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Amgen were worth $439,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in the stock. BOK Financial Private Wealth Inc. purchased a new stake in shares of Amgen during the 4th quarter worth approximately $29,000. United Community Bank bought a new position in Amgen during the fourth quarter valued at $29,000. Planned Solutions Inc. purchased a new stake in Amgen in the fourth quarter worth $30,000. Delos Wealth Advisors LLC raised its stake in shares of Amgen by 2,500.0% in the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after buying an additional 100 shares during the period. Finally, Hartford Financial Management Inc. lifted its position in shares of Amgen by 56.9% during the 4th quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock valued at $33,000 after buying an additional 41 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN stock traded down $1.24 during midday trading on Friday, reaching $312.45. The company had a trading volume of 3,518,174 shares, compared to its average volume of 2,437,626. The firm has a 50-day moving average price of $301.56 and a 200-day moving average price of $292.23. The company has a market capitalization of $167.61 billion, a P/E ratio of 44.64, a P/E/G ratio of 2.82 and a beta of 0.60. Amgen Inc. has a 1 year low of $218.44 and a 1 year high of $329.72. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The company had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. During the same quarter in the previous year, the company posted $3.98 EPS. Amgen’s quarterly revenue was up 22.0% compared to the same quarter last year. On average, research analysts anticipate that Amgen Inc. will post 19.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.69% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Mizuho boosted their price objective on Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research note on Thursday, May 9th. UBS Group upped their price target on shares of Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Truist Financial reiterated a “buy” rating and issued a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. Royal Bank of Canada increased their target price on Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a research report on Friday, June 14th. Finally, Raymond James started coverage on Amgen in a report on Thursday, March 28th. They issued a “market perform” rating for the company. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $307.35.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.